Basilea Pharmaceutica Ltd. Logo
 

Oncology 2010

 
 
 

Research

  • Duran GE, Lane H, Bachmann F, Sikic BI. In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and ovarian cancer variants selected for resistance to taxanes. Cancer Res. 2010; 70(8).
  • Esteve M-A, Honore S, Mckay N, Bachmann F, Lane H, Braguer D. BAL27862: A unique microtubule-targeted drug that suppresses microtubule dynamics, severs microtubules, and overcomes Bcl-2- and tubulin subtype-related drug resistance. Cancer Res. 2010; 70(8).
  • Pohlmann J, Bachmann F, Schmitt-Hoffmann A, Biringer G, Burger K, Bucher C, Schlaefle C, Pruschy M, Lane H. BAL101553: A highly soluble prodrug of the potent microtubule destabilizer BAL27862. Cancer Res. 2010; 70(8).

 

American Association of Cancer Research Annual Meeting AACR, April 2010, Washington D.C., United States of America

  • Abstract 1977 / BAL27862: A unique microtubule-targeted drug that suppresses microtubule dynamics, severs microtubules, and overcomes Bcl-2- and tubulin subtype-related drug resistance. Esteve M-A, Honore S, Mckay N, Bachmann F, Lane H, Braguer D.
  • Abstract 4412 / In vitro activity of the novel tubulin active agent BAL27862 in MDR1(+) and MDR1(-) human breast and ovarian cancer variants selected for resistance to taxanes. Duran GE, Lane H, Bachmann F, Sikic BI.
  • Abstract 4419 / BAL101553: A highly soluble prodrug of the potent microtubule destabilizer BAL27862. Pohlmann J, Bachmann F, Schmitt-Hoffmann A, Biringer G, Burger K, Bucher C, Schlaefle C, Spickermann J, Defoin R, Pruschy M, Lane H.
 
Info